Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HMGB1 Protein | 1 | 2017 | 223 | 0.58 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.42 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.30 | Why? |
| Vitamin A | 1 | 2021 | 188 | 0.20 | Why? |
| Patient Medication Knowledge | 1 | 2019 | 13 | 0.20 | Why? |
| Neurosyphilis | 1 | 2018 | 17 | 0.19 | Why? |
| Red-Cell Aplasia, Pure | 1 | 2018 | 3 | 0.19 | Why? |
| Strongyloides stercoralis | 1 | 2019 | 70 | 0.18 | Why? |
| Parvovirus B19, Human | 1 | 2018 | 73 | 0.18 | Why? |
| Strongyloidiasis | 1 | 2019 | 80 | 0.17 | Why? |
| Myelodysplastic Syndromes | 1 | 2020 | 261 | 0.17 | Why? |
| Enteritis | 1 | 2018 | 147 | 0.16 | Why? |
| Colonic Diseases | 1 | 2018 | 96 | 0.16 | Why? |
| Parvoviridae Infections | 1 | 2018 | 222 | 0.15 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.15 | Why? |
| Pulmonary Aspergillosis | 1 | 2021 | 408 | 0.15 | Why? |
| In Situ Hybridization, Fluorescence | 1 | 2016 | 207 | 0.15 | Why? |
| Lymphoma | 1 | 2020 | 522 | 0.14 | Why? |
| Serum Albumin | 1 | 2017 | 571 | 0.13 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Turkey | 5 | 2021 | 3937 | 0.12 | Why? |
| Candidemia | 1 | 2016 | 353 | 0.12 | Why? |
| Candida | 1 | 2016 | 425 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2018 | 669 | 0.11 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.11 | Why? |
| Anti-Retroviral Agents | 1 | 2019 | 1099 | 0.10 | Why? |
| Antifungal Agents | 2 | 2021 | 1828 | 0.10 | Why? |
| Pyrazines | 1 | 2021 | 1783 | 0.10 | Why? |
| Amides | 1 | 2021 | 1864 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| HIV Infections | 3 | 2019 | 11620 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| Transplant Recipients | 2 | 2021 | 4982 | 0.09 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 2426 | 0.08 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.08 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.08 | Why? |
| Signal Transduction | 1 | 2021 | 7207 | 0.07 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Immunoassay | 1 | 2019 | 4485 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Anti-Bacterial Agents | 2 | 2021 | 10083 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.05 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.05 | Why? |
| Ureaplasma | 1 | 2019 | 14 | 0.05 | Why? |
| Voriconazole | 1 | 2021 | 206 | 0.05 | Why? |
| Ureaplasma Infections | 1 | 2019 | 12 | 0.05 | Why? |
| Perfusion | 1 | 2020 | 254 | 0.05 | Why? |
| Mycoplasma | 1 | 2019 | 36 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 11367 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| DEAD Box Protein 58 | 1 | 2021 | 250 | 0.05 | Why? |
| Mycoplasma Infections | 1 | 2019 | 65 | 0.05 | Why? |
| Male | 13 | 2021 | 367725 | 0.05 | Why? |
| Marital Status | 1 | 2019 | 186 | 0.04 | Why? |
| Diplopia | 1 | 2018 | 84 | 0.04 | Why? |
| Chlamydia trachomatis | 1 | 2019 | 172 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.04 | Why? |
| Neisseria gonorrhoeae | 1 | 2019 | 142 | 0.04 | Why? |
| Receptors, Immunologic | 1 | 2021 | 555 | 0.04 | Why? |
| Peptide Nucleic Acids | 1 | 2016 | 28 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Health Risk Behaviors | 1 | 2019 | 172 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2020 | 365 | 0.04 | Why? |
| Tertiary Healthcare | 1 | 2021 | 616 | 0.04 | Why? |
| Immune Tolerance | 1 | 2021 | 608 | 0.04 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.04 | Why? |
| Female | 11 | 2021 | 380317 | 0.04 | Why? |
| Central Nervous System | 1 | 2021 | 701 | 0.04 | Why? |
| Quality Indicators, Health Care | 1 | 2021 | 580 | 0.04 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2021 | 698 | 0.04 | Why? |
| Drug Resistance, Fungal | 1 | 2016 | 191 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Arthritis | 1 | 2019 | 288 | 0.04 | Why? |
| Humans | 18 | 2021 | 930598 | 0.04 | Why? |
| Gonorrhea | 1 | 2019 | 315 | 0.03 | Why? |
| Body Temperature | 1 | 2020 | 875 | 0.03 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.03 | Why? |
| Viral Tropism | 1 | 2021 | 1329 | 0.03 | Why? |
| Counseling | 1 | 2019 | 747 | 0.03 | Why? |
| Species Specificity | 1 | 2016 | 1356 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Needs Assessment | 1 | 2019 | 2352 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
| Headache | 1 | 2018 | 2257 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2021 | 7268 | 0.02 | Why? |
| Aged | 5 | 2021 | 215776 | 0.02 | Why? |
| Attitude to Health | 1 | 2019 | 2002 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Social Support | 1 | 2019 | 3183 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2019 | 10017 | 0.02 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.01 | Why? |
| Animals | 1 | 2019 | 78931 | 0.01 | Why? |
| Adolescent | 1 | 2019 | 86841 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |
Inkaya's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(128)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_